Navigation Links
BD Announces Acquisition of Cytopeia
Date:5/13/2008

Dr. van den Engh will join BD Biosciences, a segment of BD, as Vice President, Advanced Cytometry. In this role, he will manage continuing research and technology development activities in Seattle.

"In addition to access to BD Biosciences' unparalleled portfolio of cellular research tools, Cytopeia's customers will benefit from our high- quality manufacturing and global customer support capabilities," Kozy said.

BD Biosciences is a pioneer and leader in the field of flow cytometry for cellular analysis. BD manufactured the first BD FACS(TM) (fluorescence- activated cell sorting) system in 1973. Today, BD Biosciences offers broad portfolios of research and clinical flow cytometry platforms and reagents designed for cellular characterization and sorting, as well as tools to aid in drug discovery and the growth of living cells and tissue.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit http://www.bd.com.

This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products, earnings per share and income, or events or developments that BD expects
'/>"/>

SOURCE BD (Becton, Dickinson and Company)
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Chindex International Announces Shelf Registration, Related Strategy and Guidance
2. Amicus Therapeutics Announces First Quarter 2008 Financial Results
3. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008
4. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
5. China Sky One Medical, Inc. Announces Record First Quarter 2008 Results
6. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
7. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
8. SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
9. Aton Pharma Announces Distribution Partnership in Brazil
10. China Medicine Announces Solid First Quarter 2008 Results
11. Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., , NEW YORK, Dec. 2 /PRNewswire-USNewswi...entists, policy makers, and funders today convened...ative funding strategies at the inaugural Partner...Washington-based center of the Milken Institute, c...-sector collaborations needed to turn a scientific...
(Date:12/2/2009)..., , LELYSTAD, The Netherlands, Decemb...rlands based biotechnology company focusing on pro...mune therapeutics today announced that it,has appo...fficer. , Dr. Mol will be responsible for...ll management and strategic direction of the compa...
(Date:12/2/2009)..., , NANJING, China, Dec. 2 /PRNewsw...e" or the "Company") (NYSE: SCR ), a leading pha...t, manufacturing, and marketing of branded,generic...nnounced that 105 of,its drugs have been included ..."), which was issued by China,s Ministry of Human ...
(Date:12/1/2009)... Dr. Kerry Solomon announ... and has launched his redesigned website at www.D... Consulting Group. Dr. Solomon is a proven LASIK,... been professionally recognized for his substantia...gery. He is a member of Trusted LASIK Surgeons, w...
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Dutch Biotech Company Pepscan Appoints New CEO 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6
...USALEM and NEEDHAM, Massachusetts, December 10 /PR...wiss Exchange: ORIDN) today announced that,three s...be presented at the,upcoming AARC (American Associ...alifornia. These studies confirm the clinical bene...dion Microstream(R) capnography technology,and cle...
...SANNE, Switzerland, December 10 Diagnoplex, a,dev...nced the closing of a,Series A financing raising C...y Novartis Venture Fund and NeoMed, with Initiativ...rtis Venture Fund was also a seed investor in the,...stors and BMP Associés,acted as counsel to the co...
...MOUTH, Minn., Dec. 9 ev3 Inc. (Nasdaq: EVVV ),a...ay that it has received,510(k) clearance from the ...t its,EverCross 0.035" and NanoCross 0.014" periph...o begin full commercialization of the EverCross an...in January 2009. , Robert Palmisano, ev3,s presi...
Other Biology Technology:Oridion Announces Significant Medical Research to be Presented at AARC Congress 2Oridion Announces Significant Medical Research to be Presented at AARC Congress 3Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing 2Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing 3ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons 2ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons 3
(Date:12/2/2009)...tudy results strengthen the evidence that people w...e an increased risk for developing colorectal canc..., "This provides one more reason not to smoke, o... Michael J. Thun, M.D., M.S., vice president emeri... American Cancer Society. "Colorectal cancer shoul...
(Date:12/2/2009)...ce of a cancer-free status did not prompt people p...y (CT) lung-cancer screening program to pick up th... published in Cancer Epidemiology, Biomarkers & P...for Cancer Research. The December issue contains a...ld negate widespread concern in the lung screening...
(Date:12/2/2009)...iversity Medical Center researchers have figured o...ioma may be better able to resist radiation therap...g pathway in these cancer stem cells, they were ab...n a laboratory experiment. , The work builds of...ells resist the effects of radiation much better t...
Breaking Biology News(10 mins):Cigarette smoking increases colorectal cancer risk 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Discovery makes brain tumor cells more responsive to radiation 2Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 1Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 2Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 3Silenced genes as a warning sign of blood cancer 53655 1Silenced genes as a warning sign of blood cancer 53655 2Nanotechnology Transforms Pain Relief 53652 1Nanotechnology Transforms Pain Relief 53652 2Nanotechnology Transforms Pain Relief 53652 3Nanotechnology Transforms Pain Relief 53652 4
...om The Wistar Institute in Philadelphia and The Vi...mechanism involved in normal repression of the p53...le for the control of cancer in humans. , The new... intriguing approaches to diagnosing or intervenin...port on the team,s findings will be published onli...
...ervational study by researchers at the University ...n between 65 and 80 years of age who received trea...ived significantly longer than men who did not rec... December 13th issue of the Journal of the America...revention education and the resulting wide-spread ...
...mazing protein-making parts out of cells and putti...eins for a wide variety of medical uses. At the an...) Sept. 13 in San Francisco, Stanford engineering ...ch "cell-free" protein synthesis, including produc...n act as delivery trucks for a new class of potent...
Other Biology News:Novel regulatory mechanism identified for key tumor suppressor p53 2Novel regulatory mechanism identified for key tumor suppressor p53 3Older men treated for early prostate cancer live longer than those who are not 2Engineer ramps up protein production, develops versatile viral spheres 2Engineer ramps up protein production, develops versatile viral spheres 3
Chicken Anti-Plants Thaumatin 2 Polyclonal Antibody, Unconjugated from Abcam
Proteinase K Buffer from BD Biosciences Pharmingen
Rabbit Anti-VEGF Receptor 2, phospho (Tyr1214) Polyclonal Antibody, Unconjugated from Abcam
Glutathione Agarose Beads from BD Biosciences Pharmingen
Biology Products: